Erratum: Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors (Journal of Medicinal Chemistry (2010) 53 (419) DOI: 10.1021/jm901351f);Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 419-431

  Kamenecka, Ted ^a   Jiang, Rong ^a   Song, Xinyi ^a   Duckett, Derek ^a   Chen, Weimin ^a   Ling, Yuan Yuan ^a   Habel, Jeff ^a   Laughlin, John D ^a   Chambers, Jeremy ^a   Figuera Losada, Mariana ^a   Cameron, Michael D ^a   Lin, Li ^a   Ruiz, Claudia H ^a   LoGrasso, Philip V ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 MORPHOLINO 5 [2 [4 [3 (PYRIDIN 2 YL) 1H 1,2,4 TRIAZOL 1 YL]PHENYLAMINO]PYRIMIDIN 4 YL]BENZONITRILE; 3 [2 [4 (3 METHYL 1H 1,2,4 TRIAZOL 1 YL)PHENYLAMINO]PYRIMIDIN 4 YL] 5 MORPHOLINOBENZONITRILE; 4 (3 FLUORO 5 MORPHOLINOPHENYL) N [4 (3 MORPHOLINO 1H 1,2,4 TRIAZOL 1 YL)PHENYL]PYRIMIDIN 2 AMINE; 4 (3 MORPHOLINOPHENYL) N [4 [3 (PYRIDIN 3 YL) 1H 1,2,4 TRIAZOL 1 YL]PHENYL]PYRIMIDIN 2 AMINE; PYRIMIDINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 74849136062     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1000425     Document Type: Erratum

References (46)

1. Xia, X. G.; Harding, T.; Weller, M.; Bieneman, A.; Uney, J. B.; Schulz, J. B. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A 2001, 98, 10433-10438.
2. Hunot, S.; Vila, M.; Teismann, P.; Davis, R. J.; Hirsch, E. C.; Przedborski, S.; Rakic, P.; Flavell, R. A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A 2004, 101, 665-670.
3. Borsello, T.; Clarke, P. G.; Hirt, L.; Vercelli, A.; Repici, M.; Schorderet, D. F.; Bogousslavsky, J.; Bonny, C. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 2003, 9, 1180-1186.
4. Pirianov, G.; Brywe, K. G.; Mallard, C.; Edwards, A. D.; Flavell, R. A.; Hagberg, H.; Mehmet, H. Deletion of the c-Jun N-terminal kinase 3 gene protects neonatal mice against cerebral hypoxicischaemic injury. J. Cereb. Blood Flow Metab. 2007, 27, 1022-1032.
5. Mohit, A. A.; Martin, J. H.; Miller, C. A. p493F12 kinase: a novel MAPkinase expressed in a subset of neurons in the human nervous system. Neuron 1995, 14, 67-78.
6. Holtz, W. A.; Turetzky, J. M.; Jong, Y. J.; O'Malley, K. L. Oxidative stress-triggered unfolded protein response is upstream of intrinsic cell death evoked by parkinsonian mimetics. J. Neurochem. 2006, 99, 54-69.
7. Pan, J.; Xiao, Q.; Sheng, C. Y.; Hong, Z.; Yang, H. Q.; Wang, G.; Ding, J. Q.; Chen, S. D. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. Neurochem. Int. 2009, 54, 418-25.
8. Peng, J.; Mao, X. O.; Stevenson, F. F.; Hsu, M.; Andersen, J. K. The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. J. Biol. Chem. 2004, 279, 32626-32.
9. Luo, Y.; Umegaki, H.; Wang, X.; Abe, R.; Roth, G. S. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 1998, 273, 3756-64.
10. Swahn, B. M.; Huerta, F.; Kallin, E.; Malmstrom, J.; Weigelt, T.; Viklund, J.; Womack, P.; Xue, Y.; Ohberg, L. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg. Med. Chem. Lett. 2005, 15, 5095-5099.
11. Kamenecka, T.; Habel, J.; Duckett, D.; Chen, W.; Ling, Y. Y.; Frackowiak, B.; Jiang, R.; Shin, Y.; Song, X.; LoGrasso, P. Structure-activity relationships and X-ray structures describing the selectivity of aminopyrazole inhibitors for c-Jun N-terminal kinase 3 (JNK3) over p38. J. Biol. Chem. 2009, 284, 12853-12861.
12. Swahn, B. M.; Xue, Y.; Arzel, E.; Kallin, E.; Magnus, A.; Plobeck, N.; Viklund, J. Design and synthesis of 2′-anilino-4,4′-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg. Med. Chem. Lett. 2006, 16, 1397-1401.
13. Szczepankiewicz, B. G.; Kosogof, C.; Nelson, L. T.; Liu, G.; Liu, B.; Zhao, H.; Serby, M. D.; Xin, Z.; Liu, M.; Gum, R. J.; Haasch, D. L.; Wang, S.; Clampit, J. E.; Johnson, E. F.; Lubben, T. H.; Stashko, M. A.; Olejniczak, E. T.; Sun, C.; Dorwin, S. A.; Haskins, K.; Abad-Zapatero, C.; Fry, E. H.; Hutchins, C. W.; Sham, H. L.; Rondinone, C. M.; Trevillyan, J. M. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J. Med. Chem. 2006, 49, 3563-3580.
14. Zhao, H.; Serby, M. D.; Xin, Z.; Szczepankiewicz, B. G.; Liu, M.; Kosogof, C.; Liu, B.; Nelson, L. T.; Johnson, E. F.; Wang, S.; Pederson, T.; Gum, R. J.; Clampit, J. E.; Haasch, D. L.; Abad-Zapatero, C.; Fry, E. H.; Rondinone, C.; Trevillyan, J. M.; Sham, H. L.; Liu, G. Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. J. Med. Chem. 2006, 49, 4455-4458.
15. Angell, R. M.; Atkinson, F. L.; Brown, M. J.; Chuang, T. T.; Christopher, J. A.; Cichy-Knight, M.; Dunn, A. K.; Hightower, K. E.; Malkakorpi, S.; Musgrave, J. R.; Neu, M.; Rowland, P.; Shea, R. L.; Smith, J. L.; Somers, D. O.; Thomas, S. A.; Thompson, G.; Wang, R. N-(3-Cyano-4,5,6,7-tetrahydro-1- benzothien-2-yl)-amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg. Med. Chem. Lett. 2007, 17, 1296-1301.
16. Gaillard, P.; Jeanclaude-Etter, I.; Ardissone, V.; Arkinstall, S.; Cambet, Y.; Camps, M.; Chabert, C.; Church, D.; Cirillo, R.; Gretener, D.; Halazy, S.; Nichols, A.; Szyndralewiez, C.; Vitte, P. A.; Gotteland, J. P. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J. Med. Chem. 2005, 48, 4596-4607.
17. Jiang, R.; Duckett, D.; Chen, W.; Habel, J.; Ling, Y. Y.; LoGrasso, P.; Kamenecka, T. M. 3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 6378-6382.
18. Alam, M.; Beevers, R. E.; Ceska, T.; Davenport, R. J.; Dickson, K. M.; Fortunato, M.; Gowers, L.; Haughan, A. F.; James, L. A.; Jones, M. W.; Kinsella, N.; Lowe, C.; Meissner, J. W.; Nicolas, A. L.; Perry, B. G.; Phillips, D. J.; Pitt, W. R.; Platt, A.; Ratcliffe, A. J.; Sharpe, A.; Tait, L. J. Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 3463-3467.
19. Humphries, P. S.; Lafontaine, J. A.; Agree, C. S.; Alexander, D.; Chen, P.; Do, Q. Q.; Li, L. Y.; Lunney, E. A.; Rajapakse, R. J.; Siegel, K.; Timofeevski, S. L.; Wang, T.; Wilhite, D. M. Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 2099-2102.
20. LoGrasso, P.; Kamenecka, T. Inhibitors of c-jun-N-terminal kinase (JNK). Mini Rev. Med. Chem. 2008, 8, 755-766.
21. Lee, M. R.; Dominguez, C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr. Med. Chem. 2005, 12, 2979-2994.
22. Carboni, S.; Boschert, U.; Gaillard, P.; Gotteland, J. P.; Gillon, J. Y.; Vitte, P. A. AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br. J. Pharmacol. 2008, 153, 157-163.
23. Carboni, S.; Hiver, A.; Szyndralewiez, C.; Gaillard, P.; Gotteland, J. P.; Vitte, P. A. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J. Pharmacol. Exp. Ther. 2004, 310, 25-32.
24. Ember, B.; Kamenecka, T.; LoGrasso, P. Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1. Biochemistry 2008, 47, 3076-3084.
25. Fricker, M.; LoGrasso, P.; Ellis, S.; Wilkie, N.; Hunt, P.; Pollack, S. J. Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors. Arch. Biochem. Biophys. 2005, 438, 195-205.
26. Scapin, G.; Patel, S. B.; Lisnock, J.; Becker, J. W.; LoGrasso, P. V. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity. Chem. Biol. 2003, 10, 705-712.
27. Dominguez, C.; Powers, D. A.; Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Discovery Dev. 2005, 8, 421-430.
28. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 6652-6659.
29. Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 16, 1514-1519.
30. Martin, Y. C. A bioavailability score. J. Med. Chem. 2005, 48, 3164-3170.
31. Ventura, J. J.; Cogswell, P.; Flavell, R. A.; Baldwin, A. S., Jr.; Davis, R. J. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev. 2004, 18, 2905-2915.
32. Kamata, H.; Honda, S.; Maeda, S.; Chang, L.; Hirata, H.; Karin, M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005, 120, 649-661.
33. Curtin, J. F.; Donovan, M.; Cotter, T.G. Regulation and measurement of oxidative stress in apoptosis. J. Immunol. Methods 2002, 265, 49-72.
34. Fan, M.; Goodwin, M.; Vu, T.; Brantley-Finley, C.; Gaarde, W. A.; Chambers, T. C. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J. Biol. Chem. 2000, 275, 29980-29985.
35. Kharbanda, S.; Saxena, S.; Yoshida, K.; Pandey, P.; Kaneki, M.; Wang, Q.; Cheng, K.; Chen, Y. N.; Campbell, A.; Sudha, T.; Yuan, Z. M.; Narula, J.; Weichselbaum, R.; Nalin, C.; Kufe, D. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J. Biol. Chem. 2000, 275, 322-327.
36. Papadakis, E. S.; Finegan,K. G.; Wang, X.; Robinson, A. C.; Guo, C.; Kayahara, M.; Tournier, C. The regulation of Bax by c-Jun N-terminal protein kinase (JNK) is a prerequisite to the mitochondrial-induced apoptotic pathway. FEBS Lett. 2006, 580, 1320-1326.
37. Sunayama, J.; Tsuruta, F.; Masuyama, N.; Gotoh, Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J. Cell Biol. 2005, 170, 295-304.
38. Abdelli, S.; Puyal, J.; Bielmann, C.; Buchillier, V.; Abderrahmani, A.; Clarke, P. G.; Beckmann, J. S.; Bonny, C. JNK3 is abundant in insulin-secreting cells and protects against cytokine-induced apoptosis. Diabetologia 2009, 52, 1871-1880.
39. Cohen, A. E.; Ellis, P. J.; Miller, M. D.; Deacon, A. M.; Phizackerley, R. P. J. An automated system to mount cryo-cooled protein crystals on a synchrotron beamline, using compact sample cassettes and a small-scale robot. J. Appl. Crystallogr. 2002, 35, 720-726.
40. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
41. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40, 658-674.
42. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Application of Maximum Likelihood Refinement. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255.
43. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
44. PROJECT, C. C. The CCP4 Suite: Programs for Protein Crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
45. Lovell, S. C.; Davis, I. W.; Arendall, W. B., III; de Bakker, P. I. W.; Word, J. M.; Prisant, M. G.; Richardson, J. S.; Richardson, D. C. Structure validation by C-alpha geometry: phi, psi, and C-beta deviation. Proteins: Structure, Function, and Genetics 2003, 50, 437-450.
46. DeLano, W. L. The PyMol Molecular Graphics System; DeLano Scientific: San Carlos, CA, 2002.